Rybrevant®

Understanding Rybrevant®
Rybrevant® (amivantamab-vmjw) is approved by the U.S. FDA for the treatment of adults with non-small cell lung cancer (NSCLC) harboring specific EGFR mutations. It is indicated for adults with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy, and for adults with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations when used in combination with carboplatin and pemetrexed as a first-line treatment. Rybrevant® is also approved in combination with chemotherapy for adults with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or L858R substitution mutations whose disease has progressed on or after an EGFR tyrosine kinase inhibitor (TKI). Rybrevant® carries important warnings for infusion-related reactions, interstitial lung disease/pneumonitis, dermatologic toxicity, ocular toxicity, and embryo-fetal toxicity.

How Rybrevant® Works:

• EGFR and MET receptor blockade:
  A fully human bispecific antibody that targets both EGFR and MET receptors, Rybrevant® binds extracellular domains on tumor cells, inhibiting ligand-dependent signaling pathways that drive tumor growth, survival, and proliferation. 
• Immune-mediated tumor cell killing:
  By engaging immune effector cells, Rybrevant® promotes antibody-dependent cellular cytotoxicity (ADCC), leading to immune-mediated destruction of EGFR- and MET-expressing cancer cells. 
• Addresses resistance mechanisms:
  Dual targeting of EGFR and MET helps overcome resistance that develops with EGFR tyrosine kinase inhibitors (TKIs), including MET-driven escape pathways commonly seen after TKI therapy. 
• Infusion-related reaction management:
  Because infusion-related reactions are common, particularly during the first infusion, Rybrevant® requires premedication and administration by healthcare professionals trained to monitor and manage infusion reactions.

FDA Approval:
2021 – Rybrevant® received accelerated FDA approval for adults with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations whose disease progressed on or after platinum-based chemotherapy.
2024 – FDA expanded approval to include first-line use in combination with carboplatin and pemetrexed for adults with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, and approval in combination with chemotherapy for adults with NSCLC harboring EGFR exon 19 deletions or L858R substitution mutations after progression on an EGFR TKI.

For more information, please visit the Rybrevant® patient website. Speak with your healthcare provider to determine if Rybrevant® is the right treatment option for you.